Study: NCT04008732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MED2005
Description: (Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MED2005
Description: (Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MED2005
Description: (Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MED2005
Description: (Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MED2005
Description: (Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MED2005
Description: (Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrostat 0.6Mg Sublingual Tablet
Description: Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrostat 0.6Mg Sublingual Tablet
Description: Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrostat 0.6Mg Sublingual Tablet
Description: Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrostat 0.6Mg Sublingual Tablet
Description: Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrostat 0.6Mg Sublingual Tablet
Description: Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrostat 0.6Mg Sublingual Tablet
Description: Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitro Pohl
Description: to be dosed intravenously in Part 2 of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitro Pohl
Description: to be dosed intravenously in Part 2 of the study